,address1,city,state,zip,country,phone,website,industry,industryDisp,sector,sectorDisp,longBusinessSummary,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,impliedSharesOutstanding,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,52WeekChange,SandP52WeekChange,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,uuid,messageBoardId,gmtOffSetMilliseconds,currentPrice,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,315 Sigma Drive,Summerville,SC,29486,United States,(843) 900-3223,https://www.zentaris.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the Republic of Korea; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria EOOD for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries; as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.","{'maxAge': 1, 'name': 'Dr. Klaus  Paulini Ph.D.', 'title': 'Pres, CEO & Exec. Director', 'fiscalYear': 2022, 'totalPay': 365175, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,2.55,2.46,2.46,2.6793,2.55,2.46,2.46,2.6793,0.0,1.743443,-0.84126985,7088,7088,9561,7330,7330,2.54,2.89,900,1300,12868082,2.32,4.67,1.4758667,2.8206,3.06495,0.0,0.0,USD,-29087928,-2.5969698,4849126,4855880,63130,62533,1690761600,1693440000,0.012999999,0.00424,0.0055199997,6.72,0.012999999,4855880,5.988,0.4425518,1672444800,1703980800,1688083200,-22643000,-4.84,-3.15,1:25,1658361600,-3.336,1.955,-0.4175824,0.14113986,NCM,EQUITY,AEZS,AEZS,Aeterna Zentaris Inc.,Aeterna Zentaris Inc.,957965400,America/New_York,EDT,47c94313-9c0e-3607-a229-7dc731cab956,finmb_416430,-14400000,2.65,none,42186000,8.688,-14881000,230000,10.587,11.257,8719000,0.791,1.796,-0.15753001,-0.54317003,-9392375,-15723000,0.97464997,-1.70673,-1.71006,USD,
1,315 Sigma Drive,Summerville,SC,29486,United States,(843) 900-3223,https://www.zentaris.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the Republic of Korea; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria EOOD for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries; as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.","{'maxAge': 1, 'name': 'Mr. Giuliano  La Fratta', 'title': 'Sr. VP of Fin. & CFO', 'fiscalYear': 2022, 'totalPay': 266120, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,2.55,2.46,2.46,2.6793,2.55,2.46,2.46,2.6793,0.0,1.743443,-0.84126985,7088,7088,9561,7330,7330,2.54,2.89,900,1300,12868082,2.32,4.67,1.4758667,2.8206,3.06495,0.0,0.0,USD,-29087928,-2.5969698,4849126,4855880,63130,62533,1690761600,1693440000,0.012999999,0.00424,0.0055199997,6.72,0.012999999,4855880,5.988,0.4425518,1672444800,1703980800,1688083200,-22643000,-4.84,-3.15,1:25,1658361600,-3.336,1.955,-0.4175824,0.14113986,NCM,EQUITY,AEZS,AEZS,Aeterna Zentaris Inc.,Aeterna Zentaris Inc.,957965400,America/New_York,EDT,47c94313-9c0e-3607-a229-7dc731cab956,finmb_416430,-14400000,2.65,none,42186000,8.688,-14881000,230000,10.587,11.257,8719000,0.791,1.796,-0.15753001,-0.54317003,-9392375,-15723000,0.97464997,-1.70673,-1.71006,USD,
2,315 Sigma Drive,Summerville,SC,29486,United States,(843) 900-3223,https://www.zentaris.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the Republic of Korea; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria EOOD for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries; as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.","{'maxAge': 1, 'name': 'Dr. Michael  Teifel Ph.D.', 'title': 'Sr. VP of Non-Clinical Devel. & Chief Scientific Officer', 'fiscalYear': 2022, 'totalPay': 176868, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,2.55,2.46,2.46,2.6793,2.55,2.46,2.46,2.6793,0.0,1.743443,-0.84126985,7088,7088,9561,7330,7330,2.54,2.89,900,1300,12868082,2.32,4.67,1.4758667,2.8206,3.06495,0.0,0.0,USD,-29087928,-2.5969698,4849126,4855880,63130,62533,1690761600,1693440000,0.012999999,0.00424,0.0055199997,6.72,0.012999999,4855880,5.988,0.4425518,1672444800,1703980800,1688083200,-22643000,-4.84,-3.15,1:25,1658361600,-3.336,1.955,-0.4175824,0.14113986,NCM,EQUITY,AEZS,AEZS,Aeterna Zentaris Inc.,Aeterna Zentaris Inc.,957965400,America/New_York,EDT,47c94313-9c0e-3607-a229-7dc731cab956,finmb_416430,-14400000,2.65,none,42186000,8.688,-14881000,230000,10.587,11.257,8719000,0.791,1.796,-0.15753001,-0.54317003,-9392375,-15723000,0.97464997,-1.70673,-1.71006,USD,
3,315 Sigma Drive,Summerville,SC,29486,United States,(843) 900-3223,https://www.zentaris.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the Republic of Korea; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria EOOD for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries; as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.","{'maxAge': 1, 'name': 'Dr. Nicola  Ammer M.D.', 'title': 'Chief Medical Officer & Sr. VP of Clinical Devel.', 'fiscalYear': 2022, 'totalPay': 197034, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,2.55,2.46,2.46,2.6793,2.55,2.46,2.46,2.6793,0.0,1.743443,-0.84126985,7088,7088,9561,7330,7330,2.54,2.89,900,1300,12868082,2.32,4.67,1.4758667,2.8206,3.06495,0.0,0.0,USD,-29087928,-2.5969698,4849126,4855880,63130,62533,1690761600,1693440000,0.012999999,0.00424,0.0055199997,6.72,0.012999999,4855880,5.988,0.4425518,1672444800,1703980800,1688083200,-22643000,-4.84,-3.15,1:25,1658361600,-3.336,1.955,-0.4175824,0.14113986,NCM,EQUITY,AEZS,AEZS,Aeterna Zentaris Inc.,Aeterna Zentaris Inc.,957965400,America/New_York,EDT,47c94313-9c0e-3607-a229-7dc731cab956,finmb_416430,-14400000,2.65,none,42186000,8.688,-14881000,230000,10.587,11.257,8719000,0.791,1.796,-0.15753001,-0.54317003,-9392375,-15723000,0.97464997,-1.70673,-1.71006,USD,
4,315 Sigma Drive,Summerville,SC,29486,United States,(843) 900-3223,https://www.zentaris.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the Republic of Korea; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria EOOD for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries; as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.","{'maxAge': 1, 'name': 'Dr. Matthias  Gerlach', 'title': 'Sr. VP Manufacturing & Supply Chain', 'fiscalYear': 2022, 'totalPay': 224686, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,2.55,2.46,2.46,2.6793,2.55,2.46,2.46,2.6793,0.0,1.743443,-0.84126985,7088,7088,9561,7330,7330,2.54,2.89,900,1300,12868082,2.32,4.67,1.4758667,2.8206,3.06495,0.0,0.0,USD,-29087928,-2.5969698,4849126,4855880,63130,62533,1690761600,1693440000,0.012999999,0.00424,0.0055199997,6.72,0.012999999,4855880,5.988,0.4425518,1672444800,1703980800,1688083200,-22643000,-4.84,-3.15,1:25,1658361600,-3.336,1.955,-0.4175824,0.14113986,NCM,EQUITY,AEZS,AEZS,Aeterna Zentaris Inc.,Aeterna Zentaris Inc.,957965400,America/New_York,EDT,47c94313-9c0e-3607-a229-7dc731cab956,finmb_416430,-14400000,2.65,none,42186000,8.688,-14881000,230000,10.587,11.257,8719000,0.791,1.796,-0.15753001,-0.54317003,-9392375,-15723000,0.97464997,-1.70673,-1.71006,USD,
